Fig. 3
From: Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
%∆PJPS in tender and swollen joints combined. Data represent mean %ΔPJPS at months 3, 6, and 12 in component joint pairs of the 68/66-joint count, in patients receiving tofacitinib 5 or 10 mg BID or methotrexate in ORAL Start. Number of patients assessed for each joint may vary. More negative %∆PJPS values represent greater efficacy in reducing signs of inflammation. %ΔPJPS, percentage change from baseline in PJPS; AC, acromioclavicular; BID, twice daily; DIP, distal interphalangeal; IP, interphalangeal; M, month; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal; PJPS, paired joint pathology score; SC, sternoclavicular; TM, temporomandibular